Identifying the challenges of biomarkers that predict response to HER2-directed therapies

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.14, Iss.11, 2013-08, pp. : 1437-1440

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Opportunities and Challenges for Host-Directed Therapies in Tuberculosis

Current Pharmaceutical Design, Vol. 22, Iss. 17, 2016-05 ,pp. : 2599-2604

Bentham Science Publishers

Access to resources Recommend Favorite

Will Pharmacogenetics Predict Response to Therapies in Rheumatoid Arthritis?

Current Pharmacogenomics, Vol. 4, Iss. 4, 2006-01 ,pp. : 307-319

Bentham Science Publishers

Access to resources Recommend Favorite

Identifying DNA Methylation Biomarkers of Cancer Drug Response

By Maier Sabine

American Journal of PharmacoGenomics, Vol. 5, Iss. 4, 2005-01 ,pp. : 223-232

Adis International

Access to resources Recommend Favorite

HER2 Targeted Therapies for Cancer and the Gastrointestinal Tract

Current Drug Targets, Vol. 10, Iss. 6, 2009-06 ,pp. : 537-542

Bentham Science Publishers

Access to resources Recommend Favorite

Investigational therapies targeting the ErbB (EGFR, HER2, HER3, HER4) family in GI cancers

By Desai Monica Dandona Saroya Bikramajit Singh Lockhart Albert Craig

Expert Opinion on Investigational Drugs, Vol. 22, Iss. 3, 2013-03 ,pp. : 341-356

Informa Healthcare

Access to resources Recommend Favorite